Hikma Pharmaceuticals (LON:HIK) Earns Buy Rating from Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank Aktiengesellschaft in a report released on Friday,Digital Look reports. They currently have a GBX 1,950 target price on the stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential upside of 13.90% from the stock’s current price.

HIK has been the subject of a number of other research reports. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Berenberg Bank reissued a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Jefferies Financial Group lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of GBX 2,038.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,712 on Friday. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27. The stock has a market cap of £3.58 billion, a PE ratio of 9.46, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The stock has a 50-day moving average of GBX 1,529.89 and a 200-day moving average of GBX 1,451.75. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 1,865.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.